Swedish Orphan Biovitrum AB (publ) announced that Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire. Dr. Hoos brings more than three decades of experience from the global pharmaceutical industry, including positions at Amgen, GSK and Aventis and most recently as a member of the board of Patient Focused Medicine Development, a non-profit organisation dedicated to bringing the voice of patients into the development of medicines. Similar to Anders Ullman, Tony Hoos will be based in Basel, Switzerland, report to CEO Guido Oelkers and become a member of the Sobi Executive Committee.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
283.4 SEK | -1.12% | +0.93% | +6.14% |
May. 08 | Sobi Finalizes Inaugural SEK3 Billion Bond Issue | MT |
May. 08 | Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.14% | 8.98B | |
-1.19% | 89.37B | |
+2.76% | 40.65B | |
-12.32% | 32.81B | |
+52.41% | 25B | |
-17.39% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
-7.72% | 8.23B | |
-8.25% | 7B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Swedish Orphan Biovitrum AB Announces Executive Changes